GlassScriptPhysician profile
Casey N Gashti
NPI 1285762252
$73,865.50
in general payments reported to CMS, 2019-2025
16 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $15K · 2021: $6,499 · 2022: $1,492 · 2023: $9,381 · 2024: $16K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $6,813 · Travel and Lodging: $6,229 · Food and Beverage: $2,624 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,850.00 |
| Consulting Fee | $6,813.26 |
| Travel and Lodging | $6,228.85 |
| Food and Beverage | $2,623.79 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $62,978.26 | 2019-2025 | Nxstage System One, Nxstage Cartridge Express, Nxstage Pureflow Solution |
| Fresenius USA Marketing, INC. | $6,894.42 | 2024-2025 | Nxstage System One |
| Horizon Therapeutics Plc | $2,970.49 | 2020 | |
| Amgen INC. | $227.42 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $135.60 | 2023-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $128.93 | 2023-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $92.51 | 2023-2024 | Tarpeyo |
| Travere Therapeutics, INC. | $86.57 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $83.11 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.10 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $57.83 | 2023-2024 | Acthar |
| Otsuka America Pharmaceutical, INC. | $47.87 | 2021-2022 | |
| Vifor Pharma, INC. | $30.00 | 2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.94 | 2025 | Jardiance |
| Ardelyx, INC. | $22.93 | 2024 | Ibsrela |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21.52 | 2023 | Ellipsys Vascular Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Gashti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.